

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/018,321
Filed: December 12, 2001
1st Inventor: M. SHIRAISHI
For: Benzazepine Derivatives, Process for The Preparation of the
Same and Uses Thereof
Atty. Dkt. No. 2614 USOP



Art Unit: 1614
Examiner: tba
Allowed:
Batch:
Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 082675381 US

DATE IN: June 20, 2002

Itemized Papers/Items:

1. This certificate and a Return Receipt Postcard (2 pgs.)
2. Transmittal Form (1 pg. X 2)
3. Request for Corrected Filing Receipt and copy of Filing Receipt (3 pgs.)

RECEIVED

JUL 24 2002


TECH CENTER 1600/2900

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231.

on this date, 6/20/02

Dated: 6/20/02


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/018,321
Filed: December 12, 2001
1st Inventor: M. SHIRAISHI
For: Benzazepine Derivatives, Process for The Preparation
of the Same and Uses Thereof
Atty. Dkt. No. 2614 USOP



Art Unit: 1614
Examiner: tba
Allowed:
Batch:
Paper No.:

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

RECEIVED
JUL 24 2002
TECH CENTER 1600/2900

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the title of the invention, as there is a typographical error in the word "the" To correct this typographical error, please rewrite the title of the invention to read as follows:

-- BENZAPEPINE DERIVATIVES, PROCESS FOR THE
PREPARATION OF THE SAME AND USES THEREOF --

Please correct the first name of inventor Aramaki to read as follows:

-- Yoshio --

A copy of the Filing Receipt is enclosed showing the corrections.

If there are any questions, please call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: June 20, 2002

(847) 383-3372
(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

COPY

JUN 20 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/018,321	12/12/2001	1614	1196	2614 USOP		37	1

CONFIRMATION NO. 2839

23115

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC
 INTELLECTUAL PROPERTY DEPARTMENT
 475 HALF DAY ROAD
 SUITE 500
 LINCOLNSHIRE, IL 60069

FILING RECEIPT



OC00000008235049

Date Mailed: 06/07/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mitsuru Shiraishi, Hyogo, JAPAN;
 Masanori Baba, Kagoshima, JAPAN;
 --Yoshio-- Yoshinori Aramaki, Hyogo, JAPAN;
 Naoyuki Kanzaki, Osaka, JAPAN;
 Osamu Nishimura, Hyogo, JAPAN;

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP00/03879 06/15/2000

Foreign Applications


JAPAN 11/170345 06/16/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No


Early Publication Request: No

Title



Benzazepine derivatives process for the preparation of the same and uses thereof
--the--

Preliminary Class
514



RECEIVED

JUL 24 2002

CENTER 1600/290

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



530 Rec'd PCT/PT 20 JUN 2002
06-21-02

Receipt
8/5/02
P U

Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/018,321	
	Filing Date	December 12, 2001	
	First Named Inventor	M. SHIRAISHI	
	Group Art Unit	1614	
	Examiner Name	tba	
Total Number of Pages in This Submission	7	Attorney Docket Number	2614 USOP

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Request for Corrected Filing
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Receipt and copy of Filing Receipt
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37,293
Signature	
Date	6/20/2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 6/20/02			
Typed or printed name	Gail L. Winokur		
Signature		Dat	6/20/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 082675381 US